Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPECT · 1 trial · 2 indications
Sensitivity and specificity of each imaging method on the diagnosis of normal or pathological examination on the visual analysis by 5 independent readers interpreting a minimum of 200 \[123I\]-FP/CIT SPECT per year, without knowing the clinical diagnosis.
| Arm | Type | Description |
|---|---|---|
| SPECT and PET | OTHER | \[123I\]-FP-CIT SPECT imaging procedure first, then \[18F\] LBT-999 PET Imaging procedure |
| PET and SPECT | OTHER | \[18F\] LBT-999 PET imaging procedure first, then \[123I\]-FP-CIT SPECT imaging procedure |
| Name | Type | Description |
|---|---|---|
| SPECT | DRUG | \[123I\]-FP-CIT SPECT imaging procedure |
| PET | DRUG | \[18F\] LBT-999 PET imaging procedure |
Inclusion Criteria: * Patients aged 35 to 80 (male or female) * Patients: * suffering from an essential tremor as defined by Elble's criteria from 2000 (excluding head tremor in decubitus and compatible with the study by the investigator) * or with Parkinson's disease as defined by the United ...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
SPECT is a diagnostic imaging agent being developed by GE HealthCare Technologies Inc. for Parkinson disease. It is studied as a [123I]-FP/CIT SPECT imaging approach to help distinguish between Parkinson's disease and essential tremor. It is a small molecule imaging agent, not a therapeutic treatment.
SPECT is being developed by GE HealthCare Technologies Inc., which trades under the ticker GEHC. The company is the sponsor of the clinical program evaluating this imaging agent for Parkinson disease and essential tremor.
SPECT is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program has enrolled 152 participants in total. SPECT is investigational and is not approved for commercial use.
SPECT has been evaluated in the Phase 3 trial NCT04265209, titled [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor. The trial enrolled 152 participants, was controlled and randomized, and was conducted in France. It is now completed.
SPECT is investigational and remains in clinical development. It has completed a Phase 3 trial but is not approved for commercial use. No approval status has been established for this imaging agent.